Fig. 1
From: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
OS in the two cohorts, in patients with PS = 0 and in patients with liver metastases. a: In all non-squamous patients, OS was 7.4 versus 15.3 months in BoM+ and BoM- (< 0.0001), respectively. b: In all squamous patients, OS was 5.0 versus 10.9 months in BoM+ and BoM- (< 0.0001), respectively. c: In non-squamous patients with PS = 0, OS was 12.0 versus 20.9 months (p < 0.0001) in patients BoM+ and BoM-, respectively. d: In squamous patients with PS = 0, OS was 5.8 versus 16.4 months (p < 0.0001) in patients BoM+ and BoM-, respectively. e: In non-squamous patients with liver metastases, OS was 4.0 versus 8.4 months (p < 0.0001) in patients BoM+ and BoM-, respectively. f: In squamous patients with liver metastases, OS was 5.5 versus 6.4 months (p = 0.48) in patients BoM+ and BoM-, respectively